NeoGenomics, Inc.
NEOHealthcareNASDAQDiagnostics & Research · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, NeoGenomics, Inc. focuses on Diagnostics & Research services and products. NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The $2.23B market capitalization puts NEO squarely in mid-cap range for its industry. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Market Cap
$2.23B
Beta
1.75
P/E (TTM)
—
P/E (Fwd)
50.58
EPS (TTM)
$-0.39
EPS (Fwd)
$0.34
ROE
-6.3%
ROA
-1.9%
Cash
$145.5M
Total Debt
$448.4M
Free CF
$43.9M
52W Change
119.2%
Annual Financials
Cash vs Debt
Where NEO stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NEO finished 52.10% above its 150-day moving average ($11.44) and 50.13% above its 200-day moving average ($11.59). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NEO overbought or oversold?
At the September 3, 2026 close, NEO's RSI(14) was 58.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
NeoGenomics, Inc. carries $448.4M in total debt against $145.5M in cash reserves — debt is roughly 3.1x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $43.9M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -6.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $509.7M (2022) to $727.3M (2025), reflecting a 43% increase over the period.
With a beta above 1.5, NEO tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. No single metric tells the full story. Reviewing NEO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.